

30 October 2015

## SUPERIOR KILL RATE OF BACTERIA ACHIEVED IN INDEPENDENT SURFACE HYGIENE STUDY

- **OBJ technology almost doubles the kill rate of Golden Staph**
- **Independent hygiene evaluation conducted at UWA**
- **Potential to offer greatly increased performance in the multi-billion dollar surface hygiene sector**

OBJ Limited (ASX: OBJ) has received preliminary results from hygiene evaluations at the University of Western Australia's Department of Microbiology & Immunology that shows an applicator containing OBJ microarray technology resulted in superior bacteria kill to the same disinfectant agents applied using traditional methods.

These encouraging results represent further progress in the Company's surface hygiene development program that commenced in 2010 to explore the impact of magnetic microarrays on the microfluidic flow conditions in hard surfaces that limit the penetration by antiseptic agents.

Surface hygiene is a multi-billion dollar commercial sector involving household cleaning, hospital disinfection and industrial cleaning applications. This program utilises the same R&D technologies as the Company's skincare activities and further demonstrates the wide-ranging applications for OBJ's technologies.

The study was conducted by Professor Tom Riley and demonstrated that the OBJ technology almost doubled the kill rate of *Staphylococcus aureus* (more commonly referred to as Golden Staph) on stainless steel, compared with traditional cleaning and disinfectant methods.

OBJ's technology achieves this by altering the surface wetting conditions at the microscopic level that allow common disinfectants such as Triclosan (Irgasan) to better penetrate the small surface cracks and fissures that harbour harmful bacteria commonly found in hospitals, households and industry.

"By increasing the penetration of common disinfectants into the surfaces that dominate our hospitals and homes we hope to significantly increase hygiene without the need for harsher or more toxic chemistry in disinfectants," said Phil Russell, project leader of OBJ's surface hygiene development program.

"By tackling the barriers to effective surface penetration using a low-cost cloth-based technology, we hope to contribute to the global fight against antibiotic resistant bacteria."

OBJ commenced its work in surface hygiene in 2010 and lodged separate patent protection applications in 2011. This followed successful work by Bradford University which showed that the OBJ microarray technology could increase the penetration of common materials.

OBJ will provide an update to Shareholders on operations in due course.

### Directors

Mr Glyn Denison  
Mr Jeffrey Edwards  
Dr Chris Quirk

### Company Secretary

Mr John Palermo

### Registered Office:

284 Oxford Street  
Leederville

Western Australia 6007

Tel: +61 8 9443 3011

Fax: +61 8 9443 9960

www.obj.com.au

ABN: 72 056 482 636

30 October 2015

## ABOUT OBJ

---

OBJ develops proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors. OBJ partners companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

**For more information:**

<b>OBJ Limited:</b>	284 Oxford Street	<b>Phone:</b> +61 8 9443 3011
Mr Glyn Denison – Director	Leederville	<b>Fax:</b> +61 8 9443 9960
<a href="http://www.obj.com.au">www.obj.com.au</a>	Western Australia 6007	